NURIX THERAPEUTICS INC (NRIX) — insider trading
Health Care · NASDAQ
NURIX THERAPEUTICS INC (NRIX) has 88 reported SEC Form 4 insider transactions in our data, including 24 open-market sales among the most recent 88 (latest 2026-10-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 5,786 | — | $0 | Form 4 |
| 2026-10-02 | Ring Christine | Officer (Chief Legal Officer) | Open-market sale | 5,786 | $23.19 | $134.1K | Form 4 |
| 2026-10-02 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 5,786 | $8.72 | $50.5K | Form 4 |
| 2026-09-02 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 5,787 | — | $0 | Form 4 |
| 2026-09-02 | Ring Christine | Officer (Chief Legal Officer) | Open-market sale | 400 | $26.64 | $10.7K | Form 4 |
| 2026-09-02 | Ring Christine | Officer (Chief Legal Officer) | Open-market sale | 5,387 | $25.69 | $138.4K | Form 4 |
| 2026-09-02 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 5,787 | $8.72 | $50.5K | Form 4 |
| 2026-09-01 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 1,452 | — | $0 | Form 4 |
| 2026-09-01 | Hansen Gwenn | Officer (Chief Scientific Officer) | Open-market sale | 1,452 | $25.47 | $37.0K | Form 4 |
| 2026-09-01 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion | 1,452 | $1.86 | $2.7K | Form 4 |
| 2026-08-05 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 4,356 | — | $0 | Form 4 |
| 2026-08-05 | Hansen Gwenn | Officer (Chief Scientific Officer) | Open-market sale | 4,356 | $25.00 | $108.9K | Form 4 |
| 2026-08-05 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion | 4,356 | $1.86 | $8.1K | Form 4 |
| 2026-08-04 | Hansen Gwenn | Officer (Chief Scientific Officer) | Open-market sale | 2,611 | $24.64 | $64.3K | Form 4 |
| 2026-08-04 | Hansen Gwenn | Officer (Chief Scientific Officer) | Open-market sale | 1,500 | $23.87 | $35.8K | Form 4 |
| 2026-08-04 | van Houte Hans | Officer (Chief Financial Officer) | Open-market sale | 2,967 | $24.65 | $73.1K | Form 4 |
| 2026-08-04 | van Houte Hans | Officer (Chief Financial Officer) | Open-market sale | 1,794 | $23.89 | $42.9K | Form 4 |
| 2026-08-03 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 5,787 | — | $0 | Form 4 |
| 2026-08-03 | Ring Christine | Officer (Chief Legal Officer) | Open-market sale | 16,589 | $23.05 | $382.4K | Form 4 |
| 2026-08-03 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 5,787 | $8.72 | $50.5K | Form 4 |
| 2026-07-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 3,572 | — | $0 | Form 4 |
| 2026-07-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 2,858 | — | $0 | Form 4 |
| 2026-07-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 3,750 | — | $0 | Form 4 |
| 2026-07-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Open-market sale | 3,847 | $23.38 | $90.0K | Form 4 |
| 2026-07-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion | 3,572 | — | $0 | Form 4 |
| 2026-07-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion | 2,858 | — | $0 | Form 4 |
| 2026-07-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion | 3,750 | — | $0 | Form 4 |
| 2026-07-30 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 3,572 | — | $0 | Form 4 |
| 2026-07-30 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 2,858 | — | $0 | Form 4 |
| 2026-07-30 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 3,750 | — | $0 | Form 4 |
| 2026-07-30 | Ring Christine | Officer (Chief Legal Officer) | Open-market sale | 3,847 | $23.38 | $90.0K | Form 4 |
| 2026-07-30 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 3,572 | — | $0 | Form 4 |
| 2026-07-30 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 2,858 | — | $0 | Form 4 |
| 2026-07-30 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 3,750 | — | $0 | Form 4 |
| 2026-07-30 | van Houte Hans | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 3,572 | — | $0 | Form 4 |
| 2026-07-30 | van Houte Hans | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 2,858 | — | $0 | Form 4 |
| 2026-07-30 | van Houte Hans | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 3,750 | — | $0 | Form 4 |
| 2026-07-30 | van Houte Hans | Officer (Chief Financial Officer) | Open-market sale | 2,845 | $23.38 | $66.5K | Form 4 |
| 2026-07-30 | van Houte Hans | Officer (Chief Financial Officer) | Option exercise / conversion | 3,572 | — | $0 | Form 4 |
| 2026-07-30 | van Houte Hans | Officer (Chief Financial Officer) | Option exercise / conversion | 2,858 | — | $0 | Form 4 |
| 2026-07-30 | van Houte Hans | Officer (Chief Financial Officer) | Option exercise / conversion | 3,750 | — | $0 | Form 4 |
| 2026-07-02 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 5,787 | — | $0 | Form 4 |
| 2026-07-02 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 5,221 | — | $0 | Form 4 |
| 2026-07-02 | Ring Christine | Officer (Chief Legal Officer) | Open-market sale | 11,008 | $23.56 | $259.4K | Form 4 |
| 2026-07-02 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 5,787 | $8.72 | $50.5K | Form 4 |
| 2026-07-02 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 5,221 | $1.86 | $9.7K | Form 4 |
| 2026-06-25 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 15,602 | — | $0 | Form 4 |
| 2026-06-25 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 13,333 | — | $0 | Form 4 |
| 2026-06-25 | Ring Christine | Officer (Chief Legal Officer) | Open-market sale | 28,935 | $20.06 | $580.5K | Form 4 |
| 2026-06-25 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 15,602 | $8.72 | $136.0K | Form 4 |
| 2026-06-25 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 13,333 | $7.26 | $96.8K | Form 4 |
| 2026-06-25 | Hansen Gwenn | Officer (Chief Scientific Officer) | Open-market sale | 5,394 | $20.00 | $107.9K | Form 4 |
| 2026-06-02 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 3,422 | — | $0 | Form 4 |
| 2026-06-02 | Ring Christine | Officer (Chief Legal Officer) | Open-market sale | 8,148 | $16.60 | $135.3K | Form 4 |
| 2026-06-02 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 3,422 | $1.86 | $6.4K | Form 4 |
| 2026-05-15 | GREGORY JULIA P | Director | Grant / award / vesting (derivative) | 31,250 | — | $0 | Form 4 |
| 2026-05-15 | Baynes Roy D. | Director | Grant / award / vesting (derivative) | 31,250 | — | $0 | Form 4 |
| 2026-05-15 | DANSEY ROGER D | Director | Grant / award / vesting (derivative) | 31,250 | — | $0 | Form 4 |
| 2026-05-15 | Kapur Anil | Director | Grant / award / vesting (derivative) | 31,250 | — | $0 | Form 4 |
| 2026-05-15 | Lacey David L. | Director | Grant / award / vesting (derivative) | 31,250 | — | $0 | Form 4 |
| 2026-05-15 | Reinsdorf Judith A | Director | Grant / award / vesting (derivative) | 31,250 | — | $0 | Form 4 |
| 2026-05-15 | Saltzman Edward C | Director | Grant / award / vesting (derivative) | 31,250 | — | $0 | Form 4 |
| 2026-05-15 | Silva Paul M | Director | Grant / award / vesting (derivative) | 31,250 | — | $0 | Form 4 |
| 2026-05-05 | van Houte Hans | Officer (Chief Financial Officer) | Open-market sale | 582 | $17.18 | $10.0K | Form 4 |
| 2026-05-05 | van Houte Hans | Officer (Chief Financial Officer) | Open-market sale | 13,473 | $16.58 | $223.3K | Form 4 |
| 2026-05-04 | Ring Christine | Officer (Chief Legal Officer) | Open-market sale | 8,148 | $16.96 | $138.2K | Form 4 |
| 2026-05-01 | Ring Christine | Officer (Chief Legal Officer) | Open-market sale | 5,394 | $16.76 | $90.4K | Form 4 |
| 2026-04-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 2,858 | — | $0 | Form 4 |
| 2026-04-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 3,750 | — | $0 | Form 4 |
| 2026-04-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 2,000 | — | $0 | Form 4 |
| 2026-04-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Open-market sale | 3,214 | $16.65 | $53.5K | Form 4 |
| 2026-04-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion | 2,858 | — | $0 | Form 4 |
| 2026-04-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion | 3,750 | — | $0 | Form 4 |
| 2026-04-30 | Hansen Gwenn | Officer (Chief Scientific Officer) | Option exercise / conversion | 2,000 | — | $0 | Form 4 |
| 2026-04-30 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 2,858 | — | $0 | Form 4 |
| 2026-04-30 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 3,750 | — | $0 | Form 4 |
| 2026-04-30 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 2,000 | — | $0 | Form 4 |
| 2026-04-30 | Ring Christine | Officer (Chief Legal Officer) | Open-market sale | 3,214 | $16.65 | $53.5K | Form 4 |
| 2026-04-30 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 2,858 | — | $0 | Form 4 |
| 2026-04-30 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 3,750 | — | $0 | Form 4 |
| 2026-04-30 | Ring Christine | Officer (Chief Legal Officer) | Option exercise / conversion | 2,000 | — | $0 | Form 4 |
| 2026-04-30 | van Houte Hans | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 2,858 | — | $0 | Form 4 |
| 2026-04-30 | van Houte Hans | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 3,750 | — | $0 | Form 4 |
| 2026-04-30 | van Houte Hans | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 2,000 | — | $0 | Form 4 |
| 2026-04-30 | van Houte Hans | Officer (Chief Financial Officer) | Open-market sale | 2,388 | $16.65 | $39.7K | Form 4 |
| 2026-04-30 | van Houte Hans | Officer (Chief Financial Officer) | Option exercise / conversion | 2,858 | — | $0 | Form 4 |
| 2026-04-30 | van Houte Hans | Officer (Chief Financial Officer) | Option exercise / conversion | 3,750 | — | $0 | Form 4 |
| 2026-04-30 | van Houte Hans | Officer (Chief Financial Officer) | Option exercise / conversion | 2,000 | — | $0 | Form 4 |
Ask the chat about NRIX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: NURIX THERAPEUTICS INC (NRIX).
Last updated 2026-10-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.